Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact

Invenra

Invenra operates as a biotechnology company focused on early stage drug discovery

Founded 2011

Madison, United States 56 employees Series B Total: $23.10M Biotechnology, Life Sciences +1

General Information

Company Name Invenra

Founded Year 2011

Location

Madison, United States

Employees 56

Industries Biotechnology, Life Sciences, Pharmaceutical

Funding Stage Series B

Social

BounceWatch is an independent company data service, not affiliated with Invenra. To contact Invenra, visit invenra.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Invenra compare?

A PDF of Invenra and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Invenra soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Invenra

Invenra is a biotechnology company founded in 2011, headquartered in the United States. The company is dedicated to developing the next generation of best-in-class biologics, focusing on multispecific antibodies and their derivatives. Invenra's proprietary technologies, particularly the highly developable B-Body™ bispecific platform and high throughput functional screening, allow for the optimization of an unprecedented number of bispecific antibodies in phenotypic assays.

Invenra's pipeline includes immuno-oncology bispecific antibodies currently undergoing preclinical studies. Their most recent investment was a $7.00M Series B investment on 17th October 2018, led by Venture Investors.

Pricing

as listed on Oct 31, 2026

$3,750 one-time per molecule

Basic designs: $3,750 one-time per molecule

Invenra's pricing page

Funding Rounds & Investors (8)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	$7.00M	1	Venture Investors Health Fund	01 Oct 2018
Seed	$2.90M	3	Wisconsin Investment Partners, New Capital Fund +1	01 Oct 2017
Seed	$2.00M	-		01 Nov 2016
Debt Financing	$3.00M	2	Wisconsin Investment Partners, New Capital Fund	01 Jul 2016
Debt Financing	$2.00M	-		01 Aug 2015
Seed	$2.00M	-		01 Jan 2015
Debt Financing	$3.00M	2	Wisconsin Investment Partners, New Capital Fund	01 Feb 2013
Debt Financing	$1.20M	1	Rose Ventures	01 Jan 2012

FAQ About Invenra

Invenra operates as a biotechnology company focused on early stage drug discovery

Invenra was founded in 2011.

Invenra is headquartered in Madison, United States.

Invenra operates in Biotechnology, Life Sciences and Pharmaceutical.

As listed on Invenra's pricing page on Oct 31, 2026: $3,750 one-time per molecule (Basic designs: $3,750 one-time per molecule).

Invenra has approximately 56 employees.

Invenra has completed 8 funding rounds, raising a total of $23.10M. The latest funding stage is Series B.

We're actively collecting intelligence on Invenra.

Source: BounceWatch company record for Invenra, https://bouncewatch.com/company/invenra, updated 3 July 2026. When citing, please name BounceWatch and link this page.

🍪

Analytics cookies (ours + Google). We use analytics cookies (our own and Google Analytics) to understand how the site is used. Essential cookies are always on. You decide on analytics. Cookie Policy

Book a demo 30 minutes